Latest Breaking News On - Disease activity - Page 2 : comparemela.com

New Data Show RINVOQ® (upadacitinib) Demonstrated Superiority Versus DUPIXENT® (dupilumab) Across Primary and All Secondary Endpoints in an Open-Label Head-to-Head Atopic Dermatitis Study

New Data Show RINVOQ® (upadacitinib) Demonstrated Superiority Versus DUPIXENT® (dupilumab) Across Primary and All Secondary Endpoints in an Open-Label Head-to-Head Atopic Dermatitis Study
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

North chicagoUnited statesRoopal thakkarJ clin dermatolExchange commissionProgram to assess adverse eventsAbbvie incEczema areaSeverity indexWorst pruritus numerical rating scaleAtopic dermatitisImportant safetyMedication guideConsumer brief summaryFull prescribing informationAllergan aesthetics

Proposed Golimumab Biosimilar AVT05 Meets Primary Endpoints in Moderate to Severe RA

At the end of the trial, the study met its primary outcome, indicating therapeutic equivalence between the biosimilar (AVT05) and reference golimumab.

Robert wessmanMomna aliCameroni alvotechRheumatology informatics systemClinical disease activity indexDisease activityRheumatoid arthritisGlobenewswire news

Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant Cell Arteritis

Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant Cell Arteritis
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesKori wallaceProgram to assess adverse eventsExchange commissionAbbvie incArthritis foundationGiant cell arteritisImportant safetyMedication guideConsumer brief summaryMississippi riverAllergan aestheticsPrivate securities litigation reform actQuarterly reportsGiant cellAccessed april

Deucravacitinib Improves Patient-Reported Outcomes in Active Psoriatic Arthritis

The selective, allosteric tyrosine kinase 2 inhibitor demonstrated significant and clinically meaningful improvements in PROs versus placebo in a phase 2 trial of patients with PsA.

American college of rheumatologyHealth assessment questionnaireShort form healthStanford university school of medicineAmerican collegeHealth assessment questionnaire disability indexPhysical component summaryVibeke strandStanford university schoolClassification criteriaPsoriatic arthritisPsoriatic impactFunctional assessmentChronic illness therapy fatiguePatient global assessmentDisease activity

Impact of TNFi, IL-17Ai Treatments on Psoriatic Arthritis Biomarkers

These data highlight the changes observed in cytokine levels among both PsA treatment responders and non-responders.

Marie skougaardParker instituteCopenhagen university hospital bispebjergParker institute marie skougaardPsoriasis area severity indexDisease activityPsoriatic arthritisVisual analog scale